Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 14

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 14
---
 July 2024 Registered Direct Offering (and collectively
with the July 2024 Private Placement, the Offerings), with certain institutional investors, or the Investors, for the sale of (i) an aggregate
of 202,032 Depositary Shares, and (ii) an aggregate of 11,157 pre-funded warrants exercisable for Depositary Shares, or the July 2024
Pre-Funded Warrants, at a price per Depositary Share of $23.50, and a price per July 2024 Pre-Funded Warrant of $23.4975. The aggregate gross proceeds to us were approximately $5.0 million, before deducting the placement agent’s fees and related offering expenses.

| 6 |

TheJuly
2024 Pre-Funded Warrants were sold, in lieu of Depositary Shares, to the Investors such that the Investors’ purchase of Depositary Shares in the Registered Direct Offering would not otherwise result in the Investor, together with their affiliates and certain related parties, beneficially owning more than 4.99% or 9.99% of our Ordinary Shares immediately following the consummation of the July 2024 Registered Direct Offering. EachJuly 2024 Pre-Funded Warrant represents the right to purchase one Depositary Share at an exercise price of $0.0025 per share. TheJuly 2024 Pre-Funded Warrants are exercisable immediately and may be exercised at any time until theJuly 2024 Pre-Funded Warrants are exercised in full.

Additionally,
in the concurrent July 2024 Private Placement, we issued and sold to the Investors (i) Series J warrants, or the Series J Warrants, exercisable
for 213,188 Depositary Shares, and (ii) Series K warrants, or Series K Warrants, to purchase an aggregate of 213,188 Depositary Shares.
The warrants are immediately exercisable at an exercise price of $25.00 per Depositary Share, subject to adjustments for certain dilutive
equity issuances. The Series J Warrants will expire five years from the initial exercise date and the Series K Warrants will expire one
year from the initial exercise date. The Investors (together with their respective affiliates) may not exercise the warrants if the
Investor would beneficially own more than 4.99% or 9.99% (such amount to be determined at the option of the Investor upon issuance) of
the number of Ordinary Shares outstanding immediately after giving effect to such